Organic Acids
Medchemexpress LLC QTX125 trifluoroacetate | 2989537-78-0 | 99.9% | 100 MG
QTX125 TFA is the trifluoroacetate salt of QTX125, a potent and highly selective histone deacetylase 6 (HDAC6) inhibitor with reported antitumor activity. Supplied as an off-white to gray solid for research use, it is available in multiple pack sizes and should be stored sealed and protected from moisture.
- Potent and selective HDAC6 inhibitor
- High reported purity and chemical stability
- Provided as a trifluoroacetate salt for improved handling
- Suitable for in vitro and preclinical research applications
- Store sealed, away from moisture; follow cold storage recommendations
Apexbio Technology LLC DTP3 TFA 1809784-29-9 (free-base) 25mg
DTP3 TFA is a small-molecule inhibitor targeting the GADD45 /MKK7 protein-protein interaction complex It is designed to disrupt this interaction thereby modulating downstream NF- B signaling involved in tumor cell survival DTP3 TFA exerts its biological activity primarily by binding directly to MKK7 (KD 64 81 nM) inducing conformational changes that dissociate GADD45 from MKK7 resulting in activation of JNK signaling In cell-based studies DTP3 TFA selectively inhibits proliferation of cancer cell lines with elevated GADD45 expression Based on these pharmacological properties DTP3 TFA holds research potential in the study and therapeutic intervention of cancers including multiple myeloma via disruption of GADD45 /MKK7 signaling
Medchemexpress LLC PD1-PDL1-IN 1 TFA | 2005454-12-4 | >99.5% | 385.38 g/mol | C14H23N7O6 | 1 ML
PD1-PDL1-IN 1 TFA is a small-molecule programmed cell death 1 (PD-1) inhibitor supplied as the trifluoroacetic acid (TFA) salt for research use. It is intended for use as an immune-modulating reagent in PD-1/PD-L1 pathway studies, screening, and preclinical laboratory assays.
- Potent PD-1 inhibition useful for pathway and mechanism studies.
- Supplied as a TFA salt to aid solubility and handling.
- Characterized with published CAS and molecular data for identification.
- Suitable for compound screening and preclinical research applications.
- Available in small research-scale formats for laboratory use.
Medchemexpress LLC Dendrotoxin-I TFA | 99.1% | 7149.24 | 100 UG
Dendrotoxin-I TFA (DTX-I TFA) is a potent K+ channel blocker with IC50s of 0.13-50 nM for voltage-gated potassium channel subunits KV1.1, KV1.2, and KV1.6. This neurotoxin demonstrates potential for cancer research and is intended for research use only.
- Potent K+ channel blocker: Exhibits IC50s of 0.13-50 nM against voltage-gated potassium channel subunits KV1.1, KV1.2, and KV1.6.
- Neurotoxin with cancer research potential: Implicated in studies exploring its use in cancer research.
- In vivo activity: In an animal model using nude mice with MCF-7 cells, it showed a significant tumor growth inhibition effect when combined with hyperthermia.
Medchemexpress LLC Tfllr-nh2(tfa) | 1313730-19-6 | 99.6% | 761.83 | 50 MG
TFLLR-NH2 (TFA) is a selective PAR1 agonist with an EC50 of 1.9 μM. It is for research use only and not sold to patients.
- Functions as a selective PAR1 agonist.
- Stimulates concentration-dependent increases in intracellular calcium.
- Modulates E-cadherin and vimentin expression in SW620 cells.
- Induces edema in rat paw models.
- Stimulates Evans blue extravasation in various mouse tissues.
- Exhibits both contraction and relaxation effects.
Medchemexpress LLC 6bK (TFA) | 1774353-12-6 | MFCD30182289 | 99.4% | 871.94 g/mol | C43H56F3N7O9 | 5 MG
6bK TFA is a potent, selective insulin-degrading enzyme (IDE) inhibitor used in preclinical research to study insulin metabolism and glucose tolerance. It shows an in vitro IC50 of approximately 50 nM and has been reported to increase circulating insulin and improve oral glucose tolerance in high-fat-fed mice.
- Potent IDE inhibition (IC50 ≈ 50 nM).
- Selective activity for insulin-degrading enzyme.
- High purity (≈99.4%).
- Available as solid and DMSO solution in multiple pack sizes.
- Supplied with analytical documents (COA, HPLC, LCMS).
- Recommended storage: solid -20°C; in solvent -80°C (6 months) or -20°C (1 month).
Medchemexpress LLC Lys-bradykinin trifluoroacetate | 00-00-0 | 99.9% | 1188.38 g/mol | C56H85N17O12·xC2HF3O2 | 100 MG
Lys-Bradykinin TFA is the trifluoroacetate salt of the decapeptide kallidin (Lys-bradykinin), supplied as a purified peptide powder for laboratory research. It acts as a ligand for kallidin and bradykinin receptors and is involved in vascular regulation, inflammation, and pain signaling.
- TFA salt of Lys-bradykinin (kallidin).
- Decapeptide sequence: Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg.
- High purity (99.9%).
- Molecular weight 1188.38 g/mol (free base).
- Storage: powder - sealed, away from moisture and light; powder storage: -80°C for 2 years, -20°C for 1 year.
Medchemexpress LLC Ss47 Tfa | 2636072-62-1 | 99.88% | 1067.09 | 1 MG
SS47 TFA is a PROTAC-based HPK1 degrader that facilitates proteasome-mediated HPK1 degradation. This significantly improves in vivo antitumor efficacy in BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies. SS47 (TFA) is also a click chemistry reagent with an Alkyne group, capable of copper-catalyzed azide-alkyne cycloaddition (CuAAc).
- PROTAC-based HPK1 degrader
- Facilitates proteasome-mediated HPK1 degradation
- Enhances in vivo antitumor efficacy in BCMA CAR-T cell research
- Targets HPK1, an immunosuppressive regulatory kinase
- Click chemistry reagent with alkyne group
- Capable of copper-catalyzed azide-alkyne cycloaddition (CuAAc)
Medchemexpress LLC WP9QY (TFA) | 98.7% | 1340.40 | 500 UG
WP9QY TFA is a biologically active cyclic peptide that acts as a TNF-α antagonist. It is designed to mimic the critical tumor necrosis factor (TNF) recognition loop on TNF receptor I, thereby preventing interactions between TNF and its receptor. This TNF antagonist serves as a useful template for developing small molecular inhibitors to prevent inflammatory bone destruction and systemic bone loss in rheumatoid arthritis. This product is for research use only.
- Biologically active peptide
- TNF-α antagonist
- Mimics TNF recognition loop on TNF receptor I
- Prevents interactions of TNF with its receptor
- Useful for developing small molecular inhibitors
- Prevents inflammatory bone destruction in rheumatoid arthritis
- Prevents systemic bone loss in rheumatoid arthritis
Medchemexpress LLC Balixafortide TFA | 99.89% | 1978.16 | 50 MG
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. It shows 1000-fold selectivity for CXCR4 compared to a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. It is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent and exhibits anti-cancer effects.
- Potent, selective, well-tolerated peptidic CXCR4 antagonist
- High selectivity for CXCR4 (1000-fold over CXCR7)
- Blocks β-arrestin recruitment and calcium flux
- Potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent
- Anti-cancer effects
- Optimized for favorable mouse absorption, distribution, metabolism and excretion (ADME) properties with balanced plasma protein binding, greater plasma and microsomal stability
Medchemexpress LLC DV1 TFA | 98.5% | 2424.85 | 1 MG
DV1 TFA is a selective antagonist of CXC chemokine receptor 4 (CXCR4). It exhibits antiviral activity by blocking HIV-1 entry through the CXCR4 co-receptor.
- Selective antagonist for CXC chemokine receptor 4 (CXCR4)
- Exhibits antiviral activity
- Blocks HIV-1 entry through the CXCR4 co-receptor
Medchemexpress LLC FTI-2153 (TFA) | 2820151-01-5 | 99.1% | 580.62 g/mol | C27H31F3N4O5S | 10MM 1ML
FTI-2153 TFA is the trifluoroacetic acid salt of a potent farnesyltransferase inhibitor supplied for research use. It is provided as a ready-to-use 10 mM solution in DMSO (1 mL) and in solid amounts, with supporting datasheet, SDS, and COA for characterization and safe handling.
Medchemexpress LLC AS-99 TFA | 99.1% | C29H31F6N5O5S2 | 1 MG
AS-99 TFA is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor (IC50 of 0.79 μM, Kd of 0.89 μM) with anti-leukemic activity. It functions by blocking cell proliferation, inducing apoptosis and differentiation, downregulating MLL fusion target genes, and reducing the leukemia burden in vivo.
- Potent and selective ASH1L histone methyltransferase inhibitor
- Demonstrates anti-leukemic activity
- Blocks cell proliferation
- Induces apoptosis and differentiation
- Downregulates MLL fusion target genes
- Reduces leukemia burden in vivo
- Exhibits over 100-fold selectivity towards ASH1L over 20 other histone methyltransferases
- Suppresses MLL fusion driven transcriptional programs
- Leads to dose-dependent downregulation of canonical MLL fusion target genes
Medchemexpress LLC Ac-Cys-Pro-Pro-Tyr-Leu-Pro-cyclo(Lys-Tyr-Leu-Cys-Asp)-Leu-Ile-NH2 (disulfide bridge :Cys1-Cys10) | 99.0% | 1672.93 | 10 MG
KS-133 TFA is a highly selective and potent antagonist of the vascular active enteropeptide receptor 2 (VIPR2), primarily used in research for schizophrenia and cancer immune regulation.
- Highly selective and potent VIPR2 antagonist.
- Reverses tumor-promoting M2 macrophage phenotype to anti-tumor M1, altering tumor immune microenvironment.
- Inhibits tumor growth.
- Can be formulated as nanoparticles to cross the blood-brain barrier.
- Enhances anti-tumor and neuroprotective activities.
- Prevents VIPR2 over-activation, safeguarding against cognitive impairments and neuronal structural damage in mice.
- Demonstrates anti-tumor activity in murine models, synergistic with anti-PD-1 antibodies.
Apexbio Technology LLC BIBP 3226 trifluoroacetate(Synonyms: BIBP3226 TFA, BIBP3226 trifluoroacetate salt, NPY Y1 receptor antagonist BIBP3226), 2mg, CAS: 1068148-47-9.
BIBP 3226 trifluoroacetate (CAS 1068148-47-9) is a non-peptide antagonist targeting neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptors showing binding affinity with Ki values of 1 1 nM (rNPY Y1) 79 nM (hNPFF2) and 108 nM (rNPFF) BIBP 3226 competes with NPFF prevents NPFF-induced inhibition of forskolin-stimulated cAMP production and blocks NPFF-dependent hypothermic and anti-opioid effects in rodent models This compound is employed experimentally to investigate NPY/NPFF system roles in anxiety analgesia and cardiovascular regulation